Related references
Note: Only part of the references are listed.Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils
S. Narla et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance
John W. Frew et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial
Rachel G. Casseres et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa
L. Prussick et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases
Angelo V. Marzano et al.
FRONTIERS IN IMMUNOLOGY (2019)
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Megan Hohenberger et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities
B. C. Melnik et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents
Lukasz Matusiak et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Share Paper
